Literature DB >> 24841841

The role of testing for BRCA1 and BRCA2 mutations in cancer prevention.

Anne Marie McCarthy1, Katrina Armstrong1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24841841      PMCID： PMC4169670          DOI： 10.1001/jamainternmed.2014.1322

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  7 in total

1.  Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families.

Authors:  N D Kauff; P Perez-Segura; M E Robson; L Scheuer; B Siegel; A Schluger; B Rapaport; T S Frank; K Nafa; N A Ellis; G Parmigiani; K Offit
Journal:  J Med Genet       Date:  2002-08       Impact factor: 6.318

2.  Genetic/familial high-risk assessment: breast and ovarian.

Authors:  Mary B Daly; Jennifer E Axilbund; Saundra Buys; Beth Crawford; Carolyn D Farrell; Susan Friedman; Judy E Garber; Salil Goorha; Stephen B Gruber; Heather Hampel; Virginia Kaklamani; Wendy Kohlmann; Allison Kurian; Jennifer Litton; P Kelly Marcom; Robert Nussbaum; Kenneth Offit; Tuya Pal; Boris Pasche; Robert Pilarski; Gwen Reiser; Kristen Mahoney Shannon; Jeffrey R Smith; Elizabeth Swisher; Jeffrey N Weitzel
Journal:  J Natl Compr Canc Netw       Date:  2010-05       Impact factor: 11.908

3.  The future of gene patents and the implications for medicine.

Authors:  Jacob S Sherkow; Henry T Greely
Journal:  JAMA Intern Med       Date:  2013-09-23       Impact factor: 21.873

4.  Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.

Authors:  Thomas S Frank; Amie M Deffenbaugh; Julia E Reid; Mark Hulick; Brian E Ward; Beth Lingenfelter; Kathi L Gumpper; Thomas Scholl; Sean V Tavtigian; Dmitry R Pruss; Gregory C Critchfield
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

Review 5.  Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.

Authors:  Heidi D Nelson; Miranda Pappas; Bernadette Zakher; Jennifer Priest Mitchell; Leila Okinaka-Hu; Rongwei Fu
Journal:  Ann Intern Med       Date:  2014-02-18       Impact factor: 25.391

6.  Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study.

Authors:  Anne Marie McCarthy; Mirar Bristol; Tracey Fredricks; Lache Wilkins; Irene Roelfsema; Kaijun Liao; Judy A Shea; Peter Groeneveld; Susan M Domchek; Katrina Armstrong
Journal:  Cancer       Date:  2013-07-16       Impact factor: 6.860

7.  Meta-analysis of BRCA1 and BRCA2 penetrance.

Authors:  Sining Chen; Giovanni Parmigiani
Journal:  J Clin Oncol       Date:  2007-04-10       Impact factor: 44.544
  7 in total
  9 in total

Review 1.  Population genetic testing for cancer susceptibility: founder mutations to genomes.

Authors:  William D Foulkes; Bartha Maria Knoppers; Clare Turnbull
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

2.  BRCA population screening for predicting breast cancer: for or against?

Authors:  Giuseppe Lippi; Camilla Mattiuzzi; Martina Montagnana
Journal:  Ann Transl Med       Date:  2017-07

Review 3.  Looking at Thyroid Cancer from the Tumor-Suppressor Genes Point of View.

Authors:  Sadegh Rajabi; Catherine Alix-Panabières; Arshia Sharbatdar Alaei; Raziyeh Abooshahab; Heewa Shakib; Mohammad Reza Ashrafi
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

4.  Walking in the shoes of patients, not just in their genes: a patient-centered approach to genomic medicine.

Authors:  Neeraj K Arora; Bradford W Hesse; Steven B Clauser
Journal:  Patient       Date:  2015-06       Impact factor: 3.883

5.  New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing.

Authors:  Anna Kluska; Aneta Balabas; Agnieszka Paziewska; Maria Kulecka; Dorota Nowakowska; Michal Mikula; Jerzy Ostrowski
Journal:  BMC Med Genomics       Date:  2015-05-07       Impact factor: 3.063

6.  The frequency of BRCA1 founder mutation c.5266dupC (5382insC) in breast cancer patients from Ukraine.

Authors:  Ielizaveta Gorodetska; Svitlana Serga; Natalia Levkovich; Tetiana Lahuta; Ludmila Ostapchenko; Serhyi Demydov; Nikolay Anikusko; Valeriy Cheshuk; Ivan Smolanka; Svitlana Sklyar; Serhyi Polenkov; Oleksander Boichenko; Iryna Kozeretska
Journal:  Hered Cancer Clin Pract       Date:  2015-10-13       Impact factor: 2.857

7.  Predictors of BRCA1/2 genetic testing among Black women with breast cancer: a population-based study.

Authors:  Tarsha Jones; Anne Marie McCarthy; Younji Kim; Katrina Armstrong
Journal:  Cancer Med       Date:  2017-06-19       Impact factor: 4.452

8.  Prevalence of Clinically Relevant Germline BRCA Variants in a Large Unselected South African Breast and Ovarian Cancer Cohort: A Public Sector Experience.

Authors:  Nerina C Van der Merwe; Herkulaas MvE Combrink; Kholiwe S Ntaita; Jaco Oosthuizen
Journal:  Front Genet       Date:  2022-04-08       Impact factor: 4.772

9.  A novel method to detect the Mexican founder mutation BRCA1 ex9‑12del associated with breast and ovarian cancer using quantitative polymerase chain reaction and TaqMan® probes.

Authors:  Denisse Aideé Martínez-Treviño; Rafael Baltazar Reyes León-Cachón; Cynthia Villarreal-Garza; Dione Aguilar Y Méndez; Elisa Aguilar-Martínez; Hugo Alberto Barrera-Saldaña
Journal:  Mol Med Rep       Date:  2018-06-06       Impact factor: 2.952
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.